IDACIO® (adalimumab-aacf) Now Available in the United States
Fresenius Kabi announced the immediate availability in the U.S. of its citrate-free adalimumab biosimilar IDACIO® (adalimumab-aacf) for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product.